229 related articles for article (PubMed ID: 25159877)
1. Down syndrome-associated haematopoiesis abnormalities created by chromosome transfer and genome editing technologies.
Kazuki Y; Yakura Y; Abe S; Osaki M; Kajitani N; Kazuki K; Takehara S; Honma K; Suemori H; Yamazaki S; Sakuma T; Toki T; Shimizu R; Nakauchi H; Yamamoto T; Oshimura M
Sci Rep; 2014 Aug; 4():6136. PubMed ID: 25159877
[TBL] [Abstract][Full Text] [Related]
2. Pluripotent stem cell model of early hematopoiesis in Down syndrome reveals quantitative effects of short-form GATA1 protein on lineage specification.
Matsuo S; Nishinaka-Arai Y; Kazuki Y; Oshimura M; Nakahata T; Niwa A; Saito MK
PLoS One; 2021; 16(3):e0247595. PubMed ID: 33780474
[TBL] [Abstract][Full Text] [Related]
3. Modeling Down Syndrome Myeloid Leukemia by Sequential Introduction of
Barwe SP; Sebastian A; Sidhu I; Kolb EA; Gopalakrishnapillai A
Cells; 2022 Feb; 11(4):. PubMed ID: 35203280
[TBL] [Abstract][Full Text] [Related]
4. Synergistic roles of DYRK1A and GATA1 in trisomy 21 megakaryopoiesis.
Sit YT; Takasaki K; An HH; Xiao Y; Hurtz C; Gearhart PA; Zhang Z; Gadue P; French DL; Chou ST
JCI Insight; 2023 Oct; 8(23):. PubMed ID: 37906251
[TBL] [Abstract][Full Text] [Related]
5. Perturbed hematopoiesis in the Tc1 mouse model of Down syndrome.
Alford KA; Slender A; Vanes L; Li Z; Fisher EM; Nizetic D; Orkin SH; Roberts I; Tybulewicz VL
Blood; 2010 Apr; 115(14):2928-37. PubMed ID: 20154221
[TBL] [Abstract][Full Text] [Related]
6. Transient abnormal myelopoiesis of a newborn not associated with chromosome 21 abnormalities or GATA1 mutations.
Nakashima MO; Shetty S; Chicka M; Flagg A; Eng C; Cotta CV
Pediatr Blood Cancer; 2015 Feb; 62(2):353-355. PubMed ID: 25175265
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the understanding of transient abnormal myelopoiesis in Down syndrome.
Watanabe K
Pediatr Int; 2019 Mar; 61(3):222-229. PubMed ID: 30593694
[TBL] [Abstract][Full Text] [Related]
8. Single-cell transcriptomics reveal synergistic and antagonistic effects of T21 and GATA1s on hematopoiesis.
Takasaki K; Wafula EK; Kumar SS; Smith D; Gagne AL; French DL; Thom CS; Chou ST
bioRxiv; 2024 May; ():. PubMed ID: 38826323
[TBL] [Abstract][Full Text] [Related]
9. Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.
Juban G; Sakakini N; Chagraoui H; Cruz Hernandez D; Cheng Q; Soady K; Stoilova B; Garnett C; Waithe D; Otto G; Doondeea J; Usukhbayar B; Karkoulia E; Alexiou M; Strouboulis J; Morrissey E; Roberts I; Porcher C; Vyas P
Haematologica; 2021 Apr; 106(4):1106-1119. PubMed ID: 32527952
[TBL] [Abstract][Full Text] [Related]
10. The GATA1s isoform is normally down-regulated during terminal haematopoietic differentiation and over-expression leads to failure to repress MYB, CCND2 and SKI during erythroid differentiation of K562 cells.
Halsey C; Docherty M; McNeill M; Gilchrist D; Le Brocq M; Gibson B; Graham G
J Hematol Oncol; 2012 Aug; 5():45. PubMed ID: 22853316
[TBL] [Abstract][Full Text] [Related]
11. Systematic Cellular Disease Models Reveal Synergistic Interaction of Trisomy 21 and GATA1 Mutations in Hematopoietic Abnormalities.
Banno K; Omori S; Hirata K; Nawa N; Nakagawa N; Nishimura K; Ohtaka M; Nakanishi M; Sakuma T; Yamamoto T; Toki T; Ito E; Yamamoto T; Kokubu C; Takeda J; Taniguchi H; Arahori H; Wada K; Kitabatake Y; Ozono K
Cell Rep; 2016 May; 15(6):1228-41. PubMed ID: 27134169
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring oncogenic GATA1 mutants with internal deletions in transient abnormal myelopoiesis in Down syndrome.
Toki T; Kanezaki R; Kobayashi E; Kaneko H; Suzuki M; Wang R; Terui K; Kanegane H; Maeda M; Endo M; Mizuochi T; Adachi S; Hayashi Y; Yamamoto M; Shimizu R; Ito E
Blood; 2013 Apr; 121(16):3181-4. PubMed ID: 23440243
[TBL] [Abstract][Full Text] [Related]
13. Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.
Arkoun B; Robert E; Boudia F; Mazzi S; Dufour V; Siret A; Mammasse Y; Aid Z; Vieira M; Imanci A; Aglave M; Cambot M; Petermann R; Souquere S; Rameau P; Catelain C; Diot R; Tachdjian G; Hermine O; Droin N; Debili N; Plo I; Malinge S; Soler E; Raslova H; Mercher T; Vainchenker W
J Clin Invest; 2022 Jul; 132(14):. PubMed ID: 35587378
[TBL] [Abstract][Full Text] [Related]
14. GATA1 and cooperating mutations in myeloid leukaemia of Down syndrome.
Garnett C; Cruz Hernandez D; Vyas P
IUBMB Life; 2020 Jan; 72(1):119-130. PubMed ID: 31769932
[TBL] [Abstract][Full Text] [Related]
15. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
16. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
17. Complete blood count differences in a cohort of Down syndrome neonates with transient abnormal myelopoiesis screened for GATA1 pathogenic variants.
Orozco-Vela M; Corona-Rivera A; Cruz-Osorio RM; Mendoza-Maldonado L; Márquez-Mora A; Barba-Barba CC; Peña-Padilla C; Baldomero-López A; Bobadilla-Morales L; Corona-Rivera JR
Am J Med Genet A; 2020 Sep; 182(9):2085-2093. PubMed ID: 32681702
[TBL] [Abstract][Full Text] [Related]
18. miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.
Klusmann JH; Li Z; Böhmer K; Maroz A; Koch ML; Emmrich S; Godinho FJ; Orkin SH; Reinhardt D
Genes Dev; 2010 Mar; 24(5):478-90. PubMed ID: 20194440
[TBL] [Abstract][Full Text] [Related]
19. Pluripotent stem cells reveal erythroid-specific activities of the GATA1 N-terminus.
Byrska-Bishop M; VanDorn D; Campbell AE; Betensky M; Arca PR; Yao Y; Gadue P; Costa FF; Nemiroff RL; Blobel GA; French DL; Hardison RC; Weiss MJ; Chou ST
J Clin Invest; 2015 Mar; 125(3):993-1005. PubMed ID: 25621499
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome.
Labuhn M; Perkins K; Matzk S; Varghese L; Garnett C; Papaemmanuil E; Metzner M; Kennedy A; Amstislavskiy V; Risch T; Bhayadia R; Samulowski D; Hernandez DC; Stoilova B; Iotchkova V; Oppermann U; Scheer C; Yoshida K; Schwarzer A; Taub JW; Crispino JD; Weiss MJ; Hayashi Y; Taga T; Ito E; Ogawa S; Reinhardt D; Yaspo ML; Campbell PJ; Roberts I; Constantinescu SN; Vyas P; Heckl D; Klusmann JH
Cancer Cell; 2019 Aug; 36(2):123-138.e10. PubMed ID: 31303423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
